Acquisition momentum Tempus AI has visible M&A activity including potential acquisition of Personalis for 1.5B and recent open-source pathology initiatives with prestigious partners, signaling a growth-oriented sales window for integrated AI-driven diagnostics and data services.

Data asset leverage With one of the world’s largest multimodal data libraries and an operating system to access it, there is a sales opportunity to offer enterprise-grade data access, analytics, and secure data collaboration to biopharma and healthcare providers seeking faster translational insights.

Strategic partnerships Open source digital pathology initiatives and founding roles with Yale New Haven and Memorial Sloan Kettering indicate a demand for collaborative platforms; propose joint development and hosted solutions for pathology workflows and AI model training.

Clinical adoption Tempus serves physicians with AI-enabled precision medicine tooling and has traction with major healthcare institutions; target hospital systems and oncology practices for integrated decision support, imaging, and therapeutic discovery solutions.

Communication expansion Recent leadership addition in communications and active conference participation suggest a focus on market messaging and investor relations; opportunities exist to engage Tempus with thought leadership, sponsored events, and customer success narratives to accelerate deals.